Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 |
| clinicaltrials |
| NCT05072600 | Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 54 | Peking University First HospitalOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma | active not recruiting | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT02447549 | Study of Tumour Focused Radiotherapy for Bladder Cancer(RAIDER) | active not recruiting | Phase 2 | 345 | Institute of Cancer Research, United KingdomOTHER | 3 | Jun 9, 2020 | clinicaltrials |
| NCT02489890 | CIK in Treating Patients With Bladder Cancer | active not recruiting | Phase 2 | 1,500 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Mar 31, 2022source: clinicaltrials